Resources from the same session
Introduction by the chair
Presenter: Arnaud Mejean
Session: Are adjuvant immune checkpoint inhibitors a standard of care for operable high-risk urothelial and kidney cancer?
Resources:
Slides
Webcast
No
Presenter: Michiel van der Heijden
Session: Are adjuvant immune checkpoint inhibitors a standard of care for operable high-risk urothelial and kidney cancer?
Resources:
Slides
Webcast
Polling 2 (led by chair)
Presenter: Arnaud Mejean
Session: Are adjuvant immune checkpoint inhibitors a standard of care for operable high-risk urothelial and kidney cancer?
Resources:
Slides
Webcast
Q&A
Presenter: Arnaud Mejean
Session: Are adjuvant immune checkpoint inhibitors a standard of care for operable high-risk urothelial and kidney cancer?
Resources:
Slides
Webcast